Regeneron Pharmaceuticals, Inc.(REGN)Stock Performance & ReturnsNASDAQ
Returns, drawdowns and benchmark comparison
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
REGN | 83.13 B | 18.88x | 16.70% | 27.87% | $42.76 | 14.04% | 0.09x | 0.46% | $859.34 | $566.11 |
VRTX | 130.44 B | 29.80x | 12.50% | 35.00% | $17.27 | 23.54% | 0.10x | 0.00% | $560.25 | $403.16 |
ALNY | 30.87 B | 38.77x | 66.90% | 16.13% | $5.95 | 96.56% | 2.21x | 0.00% | $495.55 | $197.81 |
CRSP | 4.82 B | - | 1041.40% | 0.00% | -$4.75 | -26.10% | 0.45x | 0.00% | $75.06 | $44.12 |
RXRX | 1.96 B | - | -60.10% | 0.00% | -$0.97 | -56.58% | 0.07x | 0.00% | $7.18 | $2.77 |
NTLA | 1.66 B | - | -46.20% | 0.00% | -$3.22 | -55.44% | 0.10x | 0.00% | $28.25 | $7.95 |
Peer Valuation & Performance Analysis
Peer group analysis for Regeneron Pharmaceuticals, Inc. (REGN) compared to its primary competitors (including VRTX, ALNY, CRSP) reveals distinct metrics. REGN trades at a valuation premium compared to its competitors, with a P/E ratio of 18.9x versus the peer average of 10.1x (representing a 87% premium). This indicates that the market expects superior growth or commands a quality premium for REGN. In terms of growth, REGN's revenue growth of 16.7% lags behind the peer average of 202.9%, indicating potential market share losses or slower industry adoption. Additionally, it boasts superior profitability with a net margin of 27.9% compared to the peer average of 10.2%, demonstrating strong cost controls and pricing power.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• REGN ranks #1 in P/E ratio, #3 in revenue growth, and #2 in profit margins
• Average ranking: #2 - 🎯 Top-tier fundamentals relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-10-20 | $794.66 | $807.86 | $789.69 | $807.48 | 619,494 | +3.25% |
| 2026-10-19 | $792.59 | $800.00 | $780.83 | $782.04 | 489,600 | -1.10% |
| 2026-10-16 | $803.01 | $805.68 | $787.32 | $790.74 | 653,500 | -0.70% |
| 2026-10-15 | $802.33 | $809.49 | $792.58 | $796.34 | 798,800 | +2.31% |
| 2026-10-14 | $758.16 | $781.84 | $755.21 | $778.36 | 878,400 | +3.35% |
| 2026-10-13 | $762.49 | $765.60 | $743.57 | $753.12 | 629,600 | -1.27% |
| 2026-10-12 | $748.67 | $768.66 | $744.96 | $762.81 | 618,200 | +2.18% |
| 2026-10-09 | $737.20 | $751.27 | $732.83 | $746.54 | 466,000 | +0.94% |
| 2026-10-08 | $742.12 | $744.50 | $723.65 | $739.57 | 500,300 | -0.34% |
| 2026-10-07 | $738.05 | $753.68 | $734.18 | $742.12 | 626,400 | +0.46% |
| 2026-10-06 | $734.61 | $740.51 | $727.16 | $738.72 | 615,100 | +1.69% |
| 2026-10-05 | $734.37 | $736.42 | $722.02 | $726.47 | 694,700 | -1.19% |
| 2026-10-02 | $740.50 | $742.50 | $729.20 | $735.20 | 613,900 | +0.05% |
| 2026-10-01 | $766.53 | $777.43 | $726.02 | $734.81 | 1,042,800 | -3.09% |
| 2026-09-30 | $749.84 | $763.72 | $742.94 | $758.27 | 872,400 | +1.03% |
Explore More Analysis for REGN
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.